| INTRODUCTION
Hepatitis B virus infection is a major public health problem worldwide.
Roughly 30% of the world's population show serological evidence of current or past HBV infection. 1 In China, the prevalence of HBsAg for 1-59 years was 7.18% in 2006, turning China from a high endemic area of HBV into an intermediate endemic area. 2 Liver fibrosis is the common consequence of chronic hepatitis B virus infection, which can lead to the formation of cirrhosis. Accurate assessment of liver fibrosis is especially essential for the management of patients with liver cirrhosis (LC) which is accompanied by distortion of the hepatic vasculature. 3 This distortion results in increased resistance to portal blood flow and hence in portal hypertension and in hepatic synthetic dysfunction. 4 Liver biopsy is considered to be the gold standard for diagnosis of cirrhosis and staging of fibrosis. 5 However, it has many limitations, such as sampling error, subjectivity in reporting, high costs, the risks of bleeding and pneumothorax, discomfort to the patient, and the need for training and infrastructure in low-and middle-income countries (LMICs). 6 As a result, many non-invasive methods such as serum markers and transient elastography have been reported.
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More and more studies suggest that FibroScan exhibited better diagnostic performance in patients with normal serum bilirubin and
Co-first author: Bin Wei and Shu Feng contribute equally to this work. alanine aminotransferase (ALT) level, and is superior to other noninvasive methods for the diagnosis of liver fibrosis and cirrhosis in patients with HBV infection.
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Recently, glycoproteomic biomarker screening studies show that 
| METHODS

| Patients
Two hundred and sixty-three HBV infected patients with normal biliru- 
| FibroScan
In ALT, alanine aminotransferase; AST, aspartate amino transferase; A/G, albumin/globulin; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; RBC, red blood cell; APRI, AST-to-platelet ratio; AAR, AST to ALT ratio; RPR, RDW to platelet ratio.
indicated in Figure 1 . Meanwhile, we defined significant fibrosis as a fibrosis score of 2 or more (≥F2), and cirrhosis as fibrosis score of 4 (F4) on the basis of the METAVIR score (F0, no fibrosis; F1, portal fibrosis without septa; F2, few septa; F3, numerous septa without cirrhosis; F4, cirrhosis). 40 
| Laboratory testing
At the time of blood withdrawal, all patients underwent FibroScan. 
| Measurement of M2BPGi
The serum M2BPGi level was measured based on a lectin-antibody sandwich immunoassay using a fully automatic HISCL-5000 immunoanalyzer (Sysmex Corporation, Hyogo, Japan). 15 Glycosylated M2BP
was captured by WFA immobilized on magnetic beads. Then, the bound product was assayed with an antihuman M2BP monoclonal antibody linked to alkaline phosphatase (ALP-αM2BP). The lot number of HISCL ® M2BPGi assay kit and HISCL ® M2BPGi control is BS0012
and BX457600, respectively. The measured values of M2BPGi conjugated to WFA were indexed with the obtained values using the following equation:
Where 
| RESULTS
| Patient characteristics
The baseline characteristics of the 228 patients are summarized in 
| Factors associated with FibroScan
FibroScan values was significantly, positively correlated with age and the levels of total bilirubin, ALT, AST, globulin, alkaline phosphatase (ALP), γ-glutamyl transpeptidase (GGT), APRI, FIB-4 index, RPR. It was negatively correlated with albumin, A/G, RBC and platelet count. 
| Factors associated with M2BPGi
M2BPGi levels were positively correlated with age and the levels of total bilirubin, ALT, AST, globulin, A/G, ALP, GGT. It was negatively correlated with albumin, A/G, RBC, hemoglobin, platelet count. Our results showed that the independent variables of total bilirubin, albumin, globulin, A/G, ALP, hemoglobin, platelet count remained in the final equation (Table 2 ).
| M2BPGi value and fibrosis stage
Serum M2BPGi values for each fibrosis stage were exhibited in We analyzed the proportions of the patients with different
M2BPGi levels stratified by the fibrosis stage ( Figure 3 ). The propor- 
| Correlations between M2BPGi and other indicators
The correlation coefficient between M2BPGi and APRI was 0.587 
| Diagnostic performance of M2BPGi for significant fibrosis and cirrhosis and compared with other indicators
Receiver operating characteristic curve analysis was performed to evaluate the diagnostic accuracy of M2BPGi for significant fibrosis (≥F2) ( Figure 4A ) and cirrhosis (≥F4) ( Figure 4B 
| DISCUSSION
In this study, we evaluated serum M2BPGi for assessing liver fibrosis stages in Chinese patients with HBV infection. M2BPGi is a significant factor closely associated with FibroScan liver stiffness measurements.
This study demonstrated M2BPGi levels in HBV infected patients were increased with the progression of fibrosis stage, which is in consistent with several previous studies. 27, 34 Based on our research, we found that M2BPGi yielded higher diagnostic accuracy in cirrhosis than significant fibrosis. Meanwhile, the performance of M2BPGi was superior to other surrogate serum markers such as APRI, FIB-4 index, AAR, and RPR for diagnosing cirrhosis, indicating that M2BPGi is an accurate and reliable surrogate marker for patient with HBV infection.
M2BP is a kind of secretory glycoprotein and secreted from many cell types, including hepatocytes. It has been shown to modulate many processes, particularly those related to cell adhesion. M2BP also interacts with a number of fibrosis-associated extracellular proteins, such as collagens IV-VI, fibronectin, and nidogen. 21 Kuno A et al. 15 applied a fully automated sandwich immunoassay for direct quantitation of serum M2BPGi with a measurement time of only 17 minutes. Using this method, a series of researches revealed that serum M2BPGi value was useful for assessing the stage of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), 32 primary biliary cirrhosis (PBC), 29 autoimmune hepatitis (AIH) 31 and Hepatitis C.
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According to Toshima T et al., 27 M2BPGi is superior in patients with hepatitis C than in those with hepatitis B for measurements of liver stiffness. Meanwhile, Heo JY et al. 43 reported that M2BPGi had better diagnostic accuracy in advanced fibrosis or cirrhosis for patients with chronic hepatitis B. In contrast, Zou X et al. 44 found that M2BPGi was an accurate serum indicator for assessing early stages of liver fibrosis Thus, we used it as an imperfect golden standard. In our results, M2BPGi is a significant influencing factor closely associated with FibroScan level which can also be affected by total bilirubin, albumin, GGT, platelet count. The correlation coefficient between ALT, total bilirubin, AST, total protein, albumin, ALP, GGT, platelet count and M2BPGi is similar to Zou X et al. 44 Umemura T et al. 29 and Ura K et al. 33 Meanwhile, M2BPGi level can be influenced by total bilirubin, albumin, globulin, A/G, ALP, hemoglobin, platelet count.
M2BPGi has a good diagnosis capacity for assessing the stage of liver fibrosis, especially for cirrhosis. In the process of viral hepatitis management, it is important to identify significant liver fibrosis and cirrhosis. Fibrotic change is closely correlated with hepatocarcinogenesis in patients with viral hepatitis, and the annual incidence of hepatocellular carcinoma in patients with different stage of fibrosis is varying.
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According to previous studies, M2BPGi suggested better diagnosis performance for identifying cirrhosis than significant fibrosis in patients with chronic hepatitis C, non-alcoholic fatty liver disease and autoimmune hepatitis. healthy control is warranted in our further studies.
In conclusion, M2BPGi is closely associated with fibrosis stages and can predict the severity of fibrosing liver. It showed a good correlation with other four serum biomarkers. The ROC curve indicated that M2BPGi has a considerable high diagnostic value particularly in cirrhosis. As a result, we concluded that M2BPGi can be served as a potential glycobiomarker to assess the stage of liver fibrosis, especially for the diagnosis of cirrhosis.
ACKNOWLEDGMENT
The authors would like to acknowledge the Sysmex company workers to provide HISCL ® M2BPGi assay kit. We also acknowledge other colleagues who took part in the routine detection but do not become authors.
